Search Results 231-240 of 14852 for alt

  1. Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors - Mayo Clinic

    ... (ALT) (serum glutamate pyruvate transaminase [SGPT]) ≤ 2.5 x ULN; concomitant elevations in bilirubin and AST/ALT above 1.0 X ULN are NOT permitted; also ...

  2. Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants - Mayo Clinic

    AST or ALT >2 times the upper limit of normal (ULN). Bilirubin >1.5 times the ULN unless due to Gilbert's syndrome. International normalized ratio (INR) ...

  3. A Study to Assess Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery - Mayo Clinic

    SGOT (AST) or SGPT (ALT) < 10 x upper limit of normal (ULN) for age. Adequate cardiac function for patients on doxorubicin-containing regimens (Groups C, D ...

  4. A Study to Establish an Alcoholic Hepatitis Network - Mayo Clinic

    ALT: >40 IU/mL. Based on the judgment of the investigator, subject is not capable of complying with the study requirements. Participating Mayo Clinic ...

  5. A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety - Mayo Clinic

    ALT or AST > 3 times the upper limit of normal range, or severe hepatic impairment;; Hemoglobin < 100 g/L;; NT-proBNP ≥ 500 pg/mL. If one of these criteria ...

  6. Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis - Mayo Clinic

    ALT >3 times upper limit of normal (ULN) or AST >5 times ULN during screening; Initiation or discontinuation of non-selective beta blockers within 1 month of ...

  7. Enhancing Adaptations to Exercise - Clinical Trials

    Chronic active liver disease (AST>144 IU/L or ALT>165 IU/L); Oral warfarin group medications or history of blood clotting disorders. international normalized ...

  8. PORtopulmonary Hypertension Treatment wIth maCitentan ─ a randOmized Clinical Trial

    ALT/AST >= 3 x ULN; Bilirubin >= 3 mg/dL at Screening; Any known factor or disease that might interfere with treatment compliance, study conduct, or ...

  9. A Research Study to Evaluate Safety and Efficacy of DUR-928 in Subjects With Primary Sclerosing Cholangitis (PSC) - Mayo Clinic

    ALT: males > 250 IU/L and females > 200 IU/L;; Total Bilirubin > 2.5 mg/dL. International normalized ratio (INR) ≥ 1.2. Subjects on anticoagulant therapy ...

  10. Phase III Study Of Datopotamab Deruxtecan Versus Docetaxel In Previously Treated TROP2-positive Advanced Non-squamous NSCLC Without AGA - Mayo Clinic

    Except in the setting of HBV, ALT and AST ≤ 2.5 × ULN; for participants with hepatic metastases, ALT and AST ≤ 5 × ULN. See Exclusion Criterion 10 for ...